GlassScriptPhysician profile
Luis R Navas
NPI 1770569238
$18,146.84
in general payments reported to CMS, 2019-2025
54 companies · $2,981 in 2025
The $2,981 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $1,640 · 2021: $3,140 · 2022: $2,943 · 2023: $2,453 · 2024: $3,110 · 2025: $2,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,315 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,314.60 |
| Education | $229.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,227.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,501.05 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $1,474.11 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $1,121.98 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,077.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,071.28 | 2019-2025 | |
| Amarin Pharma, INC. | $953.33 | 2019-2023 | |
| Abbvie INC. | $951.75 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $643.18 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $457.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.14 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $391.71 | 2021-2025 | |
| Dexcom, INC. | $376.34 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $353.57 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $267.93 | 2021-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Navas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.